Holen Sie sich die Stockscreener-App
8.43
3.06%
0.25
Handel nachbörslich:
8.52
0.09
+1.07%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt IOVA?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$8.18
Offen:
$8.13
24-Stunden-Volumen:
11.20M
Relative Volume:
1.86
Marktkapitalisierung:
$2.57B
Einnahmen:
$32.77M
Nettoeinkommen (Verlust:
$-440.22M
KGV:
-3.7634
EPS:
-2.24
Netto-Cashflow:
$-400.48M
1W Leistung:
-20.85%
1M Leistung:
-17.68%
6M Leistung:
-17.68%
1J Leistung:
+66.93%
1-Tages-Spanne:
$8.13
$8.65
1-Wochen-Bereich:
$8.115
$10.47
52-Wochen-Spanne:
$5.14
$18.33
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Firmenname
Iovance Biotherapeutics Inc
Sektor
Branche
Telefon
(650) 260-7120
Adresse
825 INDUSTRIAL ROAD, SAN CARLOS
Vergleichen Sie IOVA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| IOVA | 8.43 | 2.57B | 32.77M | -440.22M | -400.48M | -2.24 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-11-20 | Eingeleitet | Goldman | Buy |
| 2023-09-18 | Bestätigt | Barclays | Overweight |
| 2023-05-30 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-27 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2023-01-27 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-12-09 | Herabstufung | Goldman | Buy → Neutral |
| 2022-10-31 | Eingeleitet | Guggenheim | Neutral |
| 2022-08-18 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Stifel | Hold → Buy |
| 2021-12-07 | Fortgesetzt | Cowen | Outperform |
| 2021-06-10 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2021-05-20 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-05-19 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2021-05-19 | Herabstufung | Stifel | Buy → Hold |
| 2021-05-03 | Eingeleitet | Truist | Buy |
| 2021-04-16 | Eingeleitet | Goldman | Buy |
| 2021-03-08 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-12-15 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-10-06 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-22 | Eingeleitet | Mizuho | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-02-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-02-26 | Bestätigt | Oppenheimer | Outperform |
| 2019-12-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2019-10-01 | Eingeleitet | Stifel | Buy |
| 2019-04-29 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-02-28 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-02-07 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-12-31 | Fortgesetzt | B. Riley FBR | Buy |
| 2018-07-06 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-04-10 | Hochstufung | B. Riley FBR, Inc. | Neutral → Buy |
| 2018-03-13 | Bestätigt | B. Riley FBR, Inc. | Neutral |
| 2018-02-23 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-01-25 | Bestätigt | H.C. Wainwright | Buy |
| 2017-11-01 | Bestätigt | B. Riley FBR, Inc. | Buy |
Alle ansehen
Iovance Biotherapeutics Inc Aktie (IOVA) Neueste Nachrichten
Perceptive Advisors LLC's Strategic Acquisition in Iovance Bioth - GuruFocus.com
Iovance Biotherapeutics director Maynard sells $503k in stock - Investing.com
IOVA (Iovance Biotherapeutics) Profitability Rank : 1 (As of Sep. 2024) - GuruFocus.com
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Iovance Biotherapeutics' SWOT analysis: stock shows promise amid challenges By Investing.com - Investing.com Australia
Iovance Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Purchased by Principal Financial Group Inc. - MarketBeat
Iovance Biotherapeutics Q3: A Beat, But A SelloffNow A Buy Opportunity - Seeking Alpha
HC Wainwright Has Positive Outlook for IOVA FY2027 Earnings - MarketBeat
Earnings call: Iovance reported a third-quarter product revenue of $58.6 million - Investing.com India
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year - Yahoo Finance UK
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q3 2024 Earnings Call Transcript - Insider Monkey
IOVA Posts Narrower-Than-Expected Q3 Loss, Amtagvi Sales Drive Top line - MSN
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Gap DownTime to Sell? - MarketBeat
Iovance Biotherapeutics Inc (IOVA) Q3 2024 Earnings Call Highlig - GuruFocus.com
Iovance Biotherapeutics Inc (IOVA) Q3 2024 Earnings Call Highlights: Surpassing Revenue ... - Yahoo Finance
Q3 Earnings Estimate for IOVA Issued By HC Wainwright - MarketBeat
Iovance Biotherapeutics’ Strong Q3 2024 Performance - TipRanks
Iovance falls 12% despite Q3 beats; reaffirms 2024 revenue guidance - MSN
Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Iovance Biotherapeutics: Q3 Earnings Snapshot - San Francisco Chronicle
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024 - GlobeNewswire
Iovance Biotherapeutics earnings beat by $0.02, revenue topped estimates - Investing.com UK
Iovance Q3 Revenue Surges to $58.6M as Amtagvi Launch Gains Momentum | IOVA Stock News - StockTitan
A Peek at Iovance Biotherapeutics's Future Earnings - Benzinga
HC Wainwright Reaffirms Buy Rating for Iovance Biotherapeutics (NASDAQ:IOVA) - MarketBeat
Iovance Biotherapeutics Options Trading: A Deep Dive into Market Sentiment - Benzinga
Iovance Biotherapeutics (IOVA) Set to Announce Earnings on Thursday - MarketBeat
Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024 - The Manila Times
Iovance Biotherapeutics to Host Third Quarter and - GlobeNewswire
(IOVA) Trading Report - Stock Traders Daily
Is Iovance Biotherapeutics Stock a Buy Now? - MSN
Why Iovance Biotherapeutics (IOVA) Stock is Moving Today - GuruFocus.com
Why Iovance Biotherapeutics Stock Triumphed on Thursday - MSN
Iovance Biotherapeutics (NASDAQ:IOVA) Trading Up 6.5%Time to Buy? - MarketBeat
Smart Money Is Betting Big In IOVA Options - Benzinga
Iovance Biotherapeutics (NASDAQ:IOVA) Now Covered by Analysts at UBS Group - MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Investors Purchase High Volume of Iovance Biotherapeutics Call Options (NASDAQ:IOVA) - MarketBeat
State Street Corp's Strategic Acquisition in Iovance Biotherapeutics Inc - Yahoo Finance
First Week of October 18th Options Trading For Iovance Biotherapeutics - Nasdaq
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 5.7%Should You Buy? - MarketBeat
Is Iovance Biotherapeutics Inc. (IOVA) the Most Promising Stock to Buy According to Wall Street Analysts? - Insider Monkey
8 Most Promising Stocks to Buy According to Wall Street Analysts - Insider Monkey
Tumor Infiltrating Lymphocyte (TIL) Market Development Status 2034 |Iovance Biotherapeutics, Optera Therapeutics Corp, T – IndiaPolitics.com - IndiaPolitics.com
Is Iovance Biotherapeutics, Inc. (IOVA) the Best Growth Stock Under $10 to Buy? - Insider Monkey
Iovance Biotherapeutics (FRA:2LB) Debt-to-EBITDA : -0.22 (As of Jun. 2024) - GuruFocus.com
Is Iovance Biotherapeutics, Inc. (IOVA) the Best Stock Under $10 With High Potential? - Insider Monkey
Finanzdaten der Iovance Biotherapeutics Inc-Aktie (IOVA)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):